Skip to main content
UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center

Surgical Oncology — Lung cancer

News & Features

Lung cancer survivor, Gary Hinze, with wife, Sandie 

Meet lung cancer survivor Gary Hinze  

Musician attributes recovery to multidisciplinary cancer care.


View David Gandara in the Lung Cancer "Living Room".

Renowned oncologist discusses lung cancer screening and molecular fingerprinting as part of the Bonnie J. Addario Lung Cancer Foundation's Patient Empowerment Education Series.


Drs. Mack and Gandara © 2010 UC Regents 

A custom fit for lung cancer treatment  

See why a Bay Area physician-turned-patient chose UC Davis for his care.

New Patient Support

Peer Navigator Program 

Peer navigator program provides one-to-one peer support  

This special program matches newly-diagnosed cancer patients with cancer survivors.

Related Resources

David T. Cooke © UC RegentsThe UC Davis Comprehensive Cancer Center offers multidisciplinary care for patients with all stages of lung cancer aimed at cure or control of disease, prevention of cancer recurrence and optimization of quality of life. Your team of cancer specialists will include experts in general thoracic surgery, gastroenterology, radiation oncology, diagnostic and interventional radiology, pulmonology and medical oncology.

 

MORE LUNG CANCER INFOarrow left 

Management

Lung cancer is the second most common cancer (after skin cancer) and is the primary cause of cancer-related deaths for both men and women in the United States.

Cancer of the lungs usually originates in the cells that line the bronchi — the small tubes that channel air in and out of the lungs. Although cigarette smoking is the leading cause of lung cancer, it also can occur in people who have never smoked. Lung cancer is one of the most challenging cancers to treat, but if diagnosed and treated in the earliest stages, five-year survival rates can be over 80 percent.

There are essentially two types of lung cancer, which are treated differently:

  • Non-small cell lung cancer: Most lung cancers, about 87 percent, are non-small cell lung cancers. This type spreads more slowly than small cell lung cancer.
  • Small cell lung cancer: About 13 percent of lung cancers are small cell lung cancers. This type tends to spread quickly.

The UC Davis Health System general thoracic surgery team, which is part of the National Cancer Center Designated UC Davis Comprehensive Cancer Center, provides expansive services for the surgical treatment of non-cardiac benign and malignant diseases of the chest, including the lungs, esophagus, chest wall, airway, mediastinum (the central compartment of the chest) and diaphragm. Many therapies at UC Davis are performed using minimally invasive techniques.

Surgical interventions

Lung cancer treatment decisions depend on the type of cancer, how far it has spread and the general health of the patient. Surgery, chemotherapy, radiation or a combination of these may be necessary. Surgical options include:

  • Pneumonectomy: This is the removal of one entire lung.
  • Lobectomy: This is the removal of an entire lobe of the lung. There are two lobes in the left lung and three lobes in the right lung.
  • Segmentectomy: The removal of a part of a lobe.
  • Sleeve resection: The removal of part of the lung and air tubes (trachea or bronchi), and then reconnection of the remaining healthy sections. This procedure is done to avoid a pneumonectomy.

Video-assisted thoracic surgery (VATS)
Depending on the location and stage of the cancer, surgeons may perform an open-chest procedure or a less invasive surgical technique, such as video-assisted thoracic surgery (VATS). VATS is a minimally invasive technology that uses 3-4 one- to two-inch incisions to remove early stage lung cancers, drain excess fluid, and treat pleural infections. VATS lung surgery has resulted in reduced post-operative complications, less pain and shorter hospital stays for patients as compared to traditional open lung surgery. Only 25 percent of the lung resections in the country are performed by VATS. UC Davis Medical Center is a leader in VATS and was the first Northern California academic center to extensively use VATS to perform pulmonary resections for early stage lung cancer.

Research has shown that patients may not do well after complex surgery because of failure of their hospital to “rescue” them from complications . UC Davis has developed a detailed post-operative lung surgery recovery regimen and has a highly skilled nursing team trained in swiftly identifying and managing potential postoperative complications.

Clinical trials

CLINICAL TRIALS at UC Davis Comprehensive Cancer Center

Patients seen at the UC Davis Comprehensive Cancer Center will be eligible for trials that offer leading-edge and state-of-the-art therapy.  Several clinical trials are designed to help patients with early-stage lung cancer. 

Our general thoracic surgeons also work closely with our medical oncologists and scientists at the Jackson Laboratory–West to bring groundbreaking personalized molecular targeted therapy from “research bench to beside” for the benefit of our patients. This work is highlighted in the following PBS Newshour report.


Below are some examples of our active clinical trials:

CALGB 140503:  "Phase III Randomized Trial of Lobectomy vs. Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer (NSCLC)"
This clinical trial is designed to determine if whole lobe removal is necessary for very small lung cancers.
VIEW STUDY DETAILSarrow left

E1505:  "Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) – IIIA Non-small Cell Lung Cancer (NSCLC)"
This clinical trial will determine if chemotherapy after surgery with or without a novel blood vessel growing inhibitor is beneficial for patients with early stage lung cancer.
VIEW STUDY DETAILSarrow left

Publications

Kim AW, Cooke DT. Additional pulmonary nodules in the patient with lung cancer: controversies and challenges. Clinics in Chest Medicine. 2011 Dec; 32(4):811-25.
MOREarrow left

Cooke, David T., Nguyen, Danh V., Yang, Ying, Chen, Steven L., Yu, Cindy, Calhoun, Royce F. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Annals of Thoracic Surgery. 2010 Sept.; 90(3):943-8.
MOREarrow left

Cooke DT, Pagani FD, Kaul DR, Cooke KR, Lau CL, Riddell J IV. Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphoteric B and partial surgical resection followed by posaconazole. Mycoses. 2010 March; 1;53(2):163-7.
MOREarrow left

Evans K, Calhoun RF, Black H, Cooke DT. Disseminated primary coccidioidomycosis of the chest wall. Journal of Thoracic and Cardiovascular Surgery. 2010 Nov.;140(5):e78-9.
MOREarrow left

Cooke DT, Zheng DJ, Peterson KA, Calhoun RF 2nd. Synchronous pulmonary renal cell carcinoma metastases and primary non-small cell lung cancer. Journal of Thoracic Oncology. 2010 Jan.;5(1):140-1.
MOREarrow left

Your Team

Surgical Oncology / Thoracic Surgery
David Tom Cooke, M.D.
Assistant Professor of Clinical Surgery
Associate Program Director of the Cardiothoracic Surgery Residency

Elizabeth A. David, M.D.
Assistant Professor of Surgery

Thoracic Surgery Nurse Coordinator
Valerie Kuderer, R.N.

Physician Assistants
Jessica Harvey-Taylor, PA-C
Felicia Tanner-Corbett, PA-C

Contact Us:
Physician to Physician Referrals
1-800-4-UCDAVIS (1-800-482-3284)

General Thoracic Surgery Direct Clinical Line (Monday -Friday, 8 a.m. to 4:30 p.m.)
(916) 734-5994

Email (non-urgent): thoracic.surgery@ucdmc.ucdavis.edu

Social Media:

Twitter: Twitter@UCD_ChestHealth
Blog: UC Davis ChestHealth


Medical Oncology

David R. Gandara, M.D.
Professor of Internal Medicine, Hematology and Oncology
Director, Thoracic Oncology Program
Associate Director for Clinical Research, UC Davis Comprehensive Cancer Center

Karen Kelly, M.D.
Associate Director for Clinical Research
Phase I Clinical Director
Professor of Internal Medicine, Hematology and Oncology

Primo N. Lara, Jr., M.D.
Professor of Internal Medicine, Hematology and Oncology

Tianhong Li, M.D., Ph.D.
Assistant Professor of Internal Medicine, Hematology and Oncology
Co-Director, Phase I Program
Co-Director, Breast Cancer Research Program

Jonathan Riess, M.D.
Assistant Professor of Internal Medicine, Hematology and Oncology


Pulmonary Medicine

Ken Y. Yoneda, M.D.
Associate Professor of Internal Medicine, Pulmonary and Critical Care


Diagnostic Radiology

Ramsey Badawi, Ph.D.
Associate Professor of Radiology 
Director of Nuclear Medicine Research

Elizabeth H. Moore, M.D.
Professor of Radiology

David K. Shelton, Jr., M.D.
Professor and Chief of Radiology and Nuclear Medicine


Radiation Oncology

Megan Daly, M.D.
Assistant Professor

Ruben Fragoso, M.D., Ph.D.
Assistant Professor

Shyam Rao, M.D., Ph.D.
Assistant Professor